EP
Eupraxia Pharmaceuticals Inc.
EPRX · NASDAQ
$8.42 +3.44% (+$0.28)
1M +23.46%
Market Cap $281.9M
P/E Ratio -
Div. Yield -
ROE 43.59%
Bulios Fair Price
$4.36
48.2% downside
Current Price
$8.42
Undervalued Fair Value Overvalued
According to Bulios Fair Price, EPRX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
84 /100
Cheap P/B 2.15x
EV/EBITDA N/A
P/S N/A
Growth
100 /100
Growing Book val. growth 98.17%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 43.59%
ROA 34.41%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 16.00x
Debt/Equity 0.01x
Net debt/EBITDA N/A
Stability
42 /100
Moderate EPS volatility 28.50%
Profitable years 0
Beta 1.50x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about EPRX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
James A. Helliwell
Employees
49
Headquarters
Victoria
Upcoming events
03 NOV
Earnings
Upcoming earnings report